Iclusig®: Risk of blood clots
2013.11.25
Active substance: ponatinib
The Committee for Medicinal Products for Human Use (CHMP) recommends updating the product information of the leukaemia medicine Iclusig® (ponatinib) to include new warnings in order to minimise the risk of a higher rate of blood clots.
For more information visit: